A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Bristol-Myers Squibb
7 Hills Pharma, LLC
NRG Oncology
Pfizer
Bristol-Myers Squibb
University of Hawaii
Shanghai Henlius Biotech
Exelixis
Federation Francophone de Cancerologie Digestive
Bristol-Myers Squibb
University of Pittsburgh
TriSalus Life Sciences, Inc.
Academic and Community Cancer Research United
Incyte Corporation
University of California, Irvine
Incyte Corporation
Children's National Research Institute
Gustave Roussy, Cancer Campus, Grand Paris
Second Affiliated Hospital of Guangzhou Medical University
National Health Research Institutes, Taiwan
Xencor, Inc.
M.D. Anderson Cancer Center
Imperial College London
Incyte Corporation
University of Chicago